MANGOCEUTICALS, INC. Reports Unregistered Equity Sale

Ticker: MGRX · Form: 8-K · Filed: Jun 10, 2025 · CIK: 1938046

Mangoceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyMangoceuticals, INC. (MGRX)
Form Type8-K
Filed DateJun 10, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: unregistered-sale, equity-securities

TL;DR

Mangoceuticals sold unregistered equity, details TBD.

AI Summary

On June 2, 2025, MANGOCEUTICALS, INC. reported an unregistered sale of equity securities. The filing does not disclose specific details regarding the number of shares sold, the price per share, or the total dollar amount of the transaction.

Why It Matters

This filing indicates a potential dilution of existing shares or a capital raise, which could impact the stock price and ownership structure.

Risk Assessment

Risk Level: medium — Unregistered sales can sometimes signal financial distress or lead to dilution, requiring further investigation into the terms and parties involved.

Key Players & Entities

FAQ

What type of equity securities were sold?

The filing states 'Unregistered Sales of Equity Securities' but does not specify the type of securities.

Were these securities sold to accredited investors?

The filing does not provide information on the identity or accreditation status of the purchasers of the unregistered equity securities.

What was the total dollar amount of the unregistered equity sale?

The filing does not disclose the total dollar amount of the unregistered equity sale.

How many shares were sold in this unregistered offering?

The number of shares sold in the unregistered equity offering is not specified in this filing.

What is the purpose of this unregistered sale of equity securities?

The filing does not state the specific purpose for the unregistered sale of equity securities.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 10, 2025 regarding MANGOCEUTICALS, INC. (MGRX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing